Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide

NCT04237623 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT04237623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04237623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 18, 2020
Completion date
December 31, 2027
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transplant-related hematologic malignancy